{"entity":{"type":"insider","cik":"0001713467","url":"/insider/0001713467","json_url":"/insider/0001713467.json","name":"Deerfield Mgmt IV, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":65,"n_filings":25,"first":"2018-02-23","last":"2026-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Deerfield Mgmt IV, L.P.","source":"filing","n_filings":25,"first_seen":"2018-02-23","last_seen":"2026-03-02"}],"transactions":[{"id":6136162,"accession":"0001193805-26-000205","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-26-000205","line_url":"/filing/0001193805-26-000205","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.; Deerfield Mgmt L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Flynn James E","owner_display_name":"Deerfield Mgmt HIF, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000000.0,"shares_display":"5,000,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":25000000.0,"total_display":"25,000,000.00","total_whole":"25,000,000","shares_owned_after":6207982.0,"shares_owned_after_display":"6,207,982","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-27","filed_date":"2026-03-02","scope":"insider","n_lines":4},{"id":4579373,"accession":"0001193805-25-001648","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-25-001648","line_url":"/filing/0001193805-25-001648","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Nuvalent, Inc.","issuer_ticker":"NUVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.; Deerfield Mgmt L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":742574.0,"shares_display":"742,574","price_per_share":95.445,"price_display":"95.44","price_state":"stated","total_value":70874975.43,"total_display":"70,874,975.43","total_whole":"70,874,975","shares_owned_after":8299225.0,"shares_owned_after_display":"8,299,225","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-24","scope":"insider","n_lines":2},{"id":5143787,"accession":"0001193805-25-001155","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-25-001155","line_url":"/filing/0001193805-25-001155","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt HIF, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9375000.0,"shares_display":"9,375,000","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":30000000.0,"total_display":"30,000,000.00","total_whole":"30,000,000","shares_owned_after":9538945.0,"shares_owned_after_display":"9,538,945","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-07-31","filed_date":"2025-08-04","scope":"insider","n_lines":3},{"id":4426836,"accession":"0001193805-25-000959","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-25-000959","line_url":"/filing/0001193805-25-000959","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt IV, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":740149.0,"shares_display":"740,149","price_per_share":18.46,"price_display":"18.46","price_state":"stated","total_value":13663150.54,"total_display":"13,663,150.54","total_whole":"13,663,151","shares_owned_after":4887254.0,"shares_owned_after_display":"4,887,254","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":3218003,"accession":"0001193805-24-001348","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-24-001348","line_url":"/filing/0001193805-24-001348","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34814.0,"shares_display":"34,814","price_per_share":17.494786867352214,"price_display":"17.49","price_state":"stated","total_value":609063.51,"total_display":"609,063.51","total_whole":"609,064","shares_owned_after":5257329.0,"shares_owned_after_display":"5,257,329","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-12","filed_date":"2024-11-13","scope":"insider","n_lines":4},{"id":3217981,"accession":"0001193805-24-001348","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-24-001348","line_url":"/filing/0001193805-24-001348","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":528456.0,"shares_display":"528,456","price_per_share":18.04245197329579,"price_display":"18.04","price_state":"stated","total_value":9534642.0,"total_display":"9,534,642.00","total_whole":"9,534,642","shares_owned_after":5274736.0,"shares_owned_after_display":"5,274,736","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-11","filed_date":"2024-11-13","scope":"insider","n_lines":4},{"id":3243032,"accession":"0001193805-24-001275","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-24-001275","line_url":"/filing/0001193805-24-001275","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Nuvalent, Inc.","issuer_ticker":"NUVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Private Design Fund IV, L.P.","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000000.0,"shares_display":"2,000,000","price_per_share":97.75,"price_display":"97.75","price_state":"stated","total_value":195500000.0,"total_display":"195,500,000.00","total_whole":"195,500,000","shares_owned_after":8670512.0,"shares_owned_after_display":"8,670,512","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-22","filed_date":"2024-10-24","scope":"insider","n_lines":2},{"id":2793026,"accession":"0001193805-24-000360","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193805-24-000360","line_url":"/filing/0001193805-24-000360#line-5","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AdaptHealth Corp.","issuer_ticker":"AHCO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114906.0,"shares_display":"114,906","price_per_share":10.7,"price_display":"10.70","price_state":"stated","total_value":1229494.2,"total_display":"1,229,494.20","total_whole":"1,229,494","shares_owned_after":11528863.0,"shares_owned_after_display":"11,528,863","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-12","scope":"insider"},{"id":2793022,"accession":"0001193805-24-000360","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-24-000360","line_url":"/filing/0001193805-24-000360","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AdaptHealth Corp.","issuer_ticker":"AHCO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":182607.0,"shares_display":"182,607","price_per_share":11.021246940150158,"price_display":"11.02","price_state":"stated","total_value":2012556.84,"total_display":"2,012,556.84","total_whole":"2,012,557","shares_owned_after":11731809.0,"shares_owned_after_display":"11,731,809","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-12","scope":"insider","n_lines":2},{"id":2793010,"accession":"0001193805-24-000360","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-24-000360","line_url":"/filing/0001193805-24-000360","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AdaptHealth Corp.","issuer_ticker":"AHCO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52487.0,"shares_display":"52,487","price_per_share":10.929420427915483,"price_display":"10.93","price_state":"stated","total_value":573652.49,"total_display":"573,652.49","total_whole":"573,652","shares_owned_after":11830871.0,"shares_owned_after_display":"11,830,871","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-08","filed_date":"2024-03-12","scope":"insider","n_lines":2},{"id":2505760,"accession":"0001193805-24-000245","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-24-000245","line_url":"/filing/0001193805-24-000245","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Deerfield Mgmt IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4290617.0,"shares_display":"4,290,617","price_per_share":8.74,"price_display":"8.74","price_state":"stated","total_value":37499992.58,"total_display":"37,499,992.58","total_whole":"37,499,993","shares_owned_after":6151406.0,"shares_owned_after_display":"6,151,406","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-16","filed_date":"2024-02-16","scope":"insider","n_lines":3},{"id":6721671,"accession":"0001193805-22-001493","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-22-001493","line_url":"/filing/0001193805-22-001493#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Nuvalent, Inc.","issuer_ticker":"NUVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Mgmt HIF, L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":650000.0,"shares_display":"650,000","price_per_share":33.5,"price_display":"33.50","price_state":"stated","total_value":21775000.0,"total_display":"21,775,000.00","total_whole":"21,775,000","shares_owned_after":650000.0,"shares_owned_after_display":"650,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-03","filed_date":"2022-11-07","scope":"insider"},{"id":6241710,"accession":"0001193805-22-001296","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-22-001296","line_url":"/filing/0001193805-22-001296","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Healthcare Innovations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11111108.0,"shares_display":"11,111,108","price_per_share":3.15,"price_display":"3.15","price_state":"stated","total_value":34999990.2,"total_display":"34,999,990.20","total_whole":"34,999,990","shares_owned_after":4721200.0,"shares_owned_after_display":"4,721,200","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-16","filed_date":"2022-09-20","scope":"insider","n_lines":4},{"id":6241691,"accession":"0001193805-22-000932","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193805-22-000932","line_url":"/filing/0001193805-22-000932","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt HIF, L.P.; Flynn James E; Deerfield Mgmt IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38478.0,"shares_display":"38,478","price_per_share":25.007940121627943,"price_display":"25.01","price_state":"stated","total_value":962255.52,"total_display":"962,255.52","total_whole":"962,256","shares_owned_after":1711324.0,"shares_owned_after_display":"1,711,324","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-06","filed_date":"2022-06-08","scope":"insider","n_lines":6},{"id":5512428,"accession":"0001193805-21-001014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-21-001014","line_url":"/filing/0001193805-21-001014#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Private Design Fund IV, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":99325.0,"shares_display":"99,325","price_per_share":15.81,"price_display":"15.81","price_state":"stated","total_value":1570328.25,"total_display":"1,570,328.25","total_whole":"1,570,328","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-09","filed_date":"2021-07-13","scope":"insider"},{"id":5471352,"accession":"0001193805-21-000999","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-21-000999","line_url":"/filing/0001193805-21-000999#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6837.0,"shares_display":"6,837","price_per_share":15.869,"price_display":"15.87","price_state":"stated","total_value":108496.353,"total_display":"108,496.35","total_whole":"108,496","shares_owned_after":99325.0,"shares_owned_after_display":"99,325","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-07","filed_date":"2021-07-07","scope":"insider"},{"id":5471349,"accession":"0001193805-21-000999","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-21-000999","line_url":"/filing/0001193805-21-000999#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":49239.0,"shares_display":"49,239","price_per_share":16.195,"price_display":"16.20","price_state":"stated","total_value":797425.605,"total_display":"797,425.60","total_whole":"797,426","shares_owned_after":106162.0,"shares_owned_after_display":"106,162","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-06","filed_date":"2021-07-07","scope":"insider"},{"id":5471346,"accession":"0001193805-21-000999","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-21-000999","line_url":"/filing/0001193805-21-000999#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10599.0,"shares_display":"10,599","price_per_share":17.011,"price_display":"17.01","price_state":"stated","total_value":180299.589,"total_display":"180,299.59","total_whole":"180,300","shares_owned_after":155401.0,"shares_owned_after_display":"155,401","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-02","filed_date":"2021-07-07","scope":"insider"},{"id":5242047,"accession":"0001193805-21-000974","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-21-000974","line_url":"/filing/0001193805-21-000974","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Flynn James E; Deerfield Mgmt HIF, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt III, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":685710.0,"shares_display":"685,710","price_per_share":8.75,"price_display":"8.75","price_state":"stated","total_value":5999962.5,"total_display":"5,999,962.50","total_whole":"5,999,963","shares_owned_after":1943423.0,"shares_owned_after_display":"1,943,423","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-30","filed_date":"2021-07-02","scope":"insider","n_lines":3},{"id":4922937,"accession":"0001193805-21-000800","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193805-21-000800","line_url":"/filing/0001193805-21-000800","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Singular Genomics Systems, Inc.","issuer_ticker":"OMIC","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":33000000.0,"total_display":"33,000,000.00","total_whole":"33,000,000","shares_owned_after":1627148.0,"shares_owned_after_display":"1,627,148","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-03","scope":"insider","n_lines":2},{"id":5284358,"accession":"0001193805-21-000435","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-21-000435","line_url":"/filing/0001193805-21-000435#line-4","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Edgewise Therapeutics, Inc.","issuer_ticker":"EWTX","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":3933137.0,"shares_owned_after_display":"3,933,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-30","filed_date":"2021-03-30","scope":"insider"}],"collapsed":true,"next_cursor":"2021-03-30|5284358","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001374690","name":"Larimar Therapeutics, Inc.","url":"/issuer/0001374690","role":"Director, Ten percent owner, Other","n_filings":5,"first_seen":"2021-07-02","last_seen":"2026-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001861560","name":"Nuvalent, Inc.","url":"/issuer/0001861560","role":"Director, Ten percent owner, Other","n_filings":3,"first_seen":"2022-11-07","last_seen":"2025-11-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001671858","name":"ARS Pharmaceuticals, Inc.","url":"/issuer/0001671858","role":"Ten percent owner","n_filings":2,"first_seen":"2024-11-13","last_seen":"2025-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001725255","name":"AdaptHealth Corp.","url":"/issuer/0001725255","role":"Director, Ten percent owner, Other","n_filings":2,"first_seen":"2018-02-23","last_seen":"2024-03-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001759425","name":"Mirum Pharmaceuticals, Inc.","url":"/issuer/0001759425","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2019-07-24","last_seen":"2022-06-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001850906","name":"Singular Genomics Systems, Inc.","url":"/issuer/0001850906","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-06-03","last_seen":"2021-06-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001710072","name":"Edgewise Therapeutics, Inc.","url":"/issuer/0001710072","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-03-30","last_seen":"2021-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001528115","name":"Annexon, Inc.","url":"/issuer/0001528115","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-07-28","last_seen":"2020-07-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001787400","name":"Nkarta, Inc.","url":"/issuer/0001787400","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-07-14","last_seen":"2020-07-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001628171","name":"Revolution Medicines, Inc.","url":"/issuer/0001628171","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-02-18","last_seen":"2020-02-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001490978","name":"Schrodinger, Inc.","url":"/issuer/0001490978","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-02-10","last_seen":"2020-02-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001759138","name":"Cabaletta Bio, Inc.","url":"/issuer/0001759138","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-10-30","last_seen":"2019-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001703647","name":"Frequency Therapeutics, Inc.","url":"/issuer/0001703647","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-10-07","last_seen":"2019-10-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001655759","name":"ARVINAS INC.","url":"/issuer/0001655759","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-10-01","last_seen":"2018-10-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001713467","retrieved_at":"2026-08-24T07:08:04+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}